Physician profile
Jonathan Prest
NPI 1730539511
$7,124.19
in general payments reported to CMS, 2019-2025
10 companies · $5,702 in 2025
The $5,702 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $59.99 · 2023: $1,161 · 2024: $102 · 2025: $5,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,731 · Education: $2,558 · Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,730.88 |
| Education | $2,557.91 |
| Food and Beverage | $675.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,601.48 | 2025 | |
| Inspire Medical Systems, INC. | $1,160.08 | 2023-2024 | Inspire |
| Astellas Pharma US INC | $159.98 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $57.91 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $45.63 | 2023-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $27.50 | 2025 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $21.88 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $17.03 | 2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.60 | 2023 | Ofev |
| Genentech USA, INC. | $16.10 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Prest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.